Age-related Macular Degeneration Market Analysis

Age-related Macular Degeneration Market Analysis

To get key market trends

  Download Free Sample

Based on product, the market is segmented into Eylea, Lucentis, Beovu, Vabysmo, Syfovre, Avastin, and other products. In 2023, Eylea led the market, generating a substantial revenue of USD 4.4 billion.
 

• Eylea, a frontrunner in the global anti-VEGF therapy arena, has been a staple in wet AMD treatment since its FDA approval in 2011. This enduring presence has cultivated immense trust among both healthcare providers and patients, ensuring Eylea's market supremacy even with the advent of newer therapies.
   
• Clinical trials underscore Eylea's robust efficacy, showcasing its capability to maintain or enhance vision in numerous wet AMD patients. Coupled with an established safety profile and consistent clinical results, Eylea has firmly entrenched itself as the go-to treatment for ophthalmologists and patients alike.
   
• According to the European Medicines Agency, Eylea matches ranibizumab in preserving visual acuity for wet AMD patients. Such consistent clinical performance has cemented Eylea's role in AMD treatment protocols.
   
• With approvals for both monthly and bi-monthly dosing, Eylea offers patients tailored flexibility. This adaptability not only boosts convenience but also enhances patient adherence, a crucial factor in managing chronic conditions like AMD.
   
• Eylea's ability to customize treatment frequency to individual needs further underscores its enduring appeal among healthcare providers and patients.
   

Based on disease type, the age-related macular degeneration market is bifurcated into wet AMD and dry AMD. The wet AMD segment dominated the market with the largest revenue of USD 8.5 billion in 2023.
 

• Wet AMD stands as a leading cause of vision impairment in older adults. Characterized by abnormal blood vessel growth beneath the retina, it leads to fluid leakage and central vision damage. Current treatments primarily target the vascular endothelial growth factor (VEGF) to curb blood vessel growth and fluid buildup.
   
• As the global population ages, the incidence of wet AMD is surging. With increasing life expectancy, a growing number of individuals face risks of age-related eye diseases, amplifying the demand for effective vision-preserving treatments. The WHO forecasts a doubling of the global population aged 60 and above, reaching 2.1 billion by 2050, hinting at a potential surge in AMD cases.
   
• Many elderly patients with wet AMD find the frequent need for regular injections, often monthly or bimonthly, to be a significant burden. Innovations like Vabysmo, which may extend the intervals between doses, cater to this need for less frequent treatments. Such advancements not only enhance the quality of life but also ensure better adherence to treatment, especially for those facing mobility or access challenges.
   
• Given these dynamics, the wet AMD segment is poised for substantial growth in the coming years.
   

Based on age group, the age-related macular degeneration market is segmented into 50–64 years, 65–74 years, and 75 and above. The 75 and above segment is projected to reach USD 12.3 billion by 2032.
 

• For patients aged 75 and above, primary treatments for age-related macular degeneration (AMD) encompass anti-VEGF injections, laser therapy, photodynamic therapy, and nutritional supplements. Commonly used anti-VEGF agents like Lucentis, Eylea, and Avastin play a crucial role in preventing vision loss for wet AMD patients.
   
• These agents function by curbing abnormal blood vessel growth and leakage in the retina. In contrast, for the more slowly progressing dry AMD, healthcare providers might suggest lifestyle changes and dietary supplements rich in antioxidants, zinc, and copper to potentially decelerate the disease's progression.
   
• With life expectancy on the rise, the demographic aged 75 and above is expanding rapidly, coinciding with the highest prevalence of AMD. Projections from the UN indicate a tripling of the population aged 80 and older, from 143 million in 2019 to 426 million by 2050. This demographic shift is likely to result in a corresponding uptick in AMD cases, underscoring the urgency for accessible treatments.
   
• Given these trends, the segment is set for notable growth in the foreseeable future.
   

The age-related macular degeneration market is segmented by distribution channel into hospital pharmacies, specialty pharmacies, and E-commerce. In 2023, the hospital pharmacies segment was valued at USD 5.4 billion.
 

• Hospital pharmacies often work hand-in-hand with insurance providers to navigate the financial challenges of AMD treatments, easing the burden on patients. Beyond this, hospitals frequently provide patient assistance programs and financial counseling, a level of support that standalone clinics might lack. This financial backing underscores the pivotal role of hospital pharmacies in the care of AMD patients.
   
• For many older adults grappling with AMD, hospital pharmacies present distinct advantages. Given that these patients often seek various healthcare services within the hospital, the centralized nature of hospital pharmacies streamlines access. This is especially crucial for those with mobility challenges or those who find it difficult to juggle appointments across different venues.
   

In 2023, the U.S. age-related macular degeneration market was valued at USD 4.2 billion, with projections indicating a growth at a CAGR of 9.9% over the forecast period.

• In the U.S., the population aged 65 and older is on the rise, and this demographic is primarily affected by age-related macular degeneration (AMD). Data from the U.S. Census Bureau forecasts that the number of Americans aged 65 and older will nearly double, soaring from 52 million in 2018 to an anticipated 95 million by 2060. This demographic shift significantly drives the demand for AMD treatments, given that the incidence of AMD escalates with age. As the elderly population grows, so too will the cases of AMD, underscoring the need for more advanced and accessible treatment options.
   
• The U.S. leads in biopharmaceutical research and development, making strides in AMD treatments. Major pharmaceutical companies and research institutions in the U.S. are at the forefront, developing advanced treatments for AMD, including gene therapies, extended-release formulations, and combination therapies. This vibrant research landscape solidifies the U.S.'s position as a pivotal player in crafting innovative AMD treatments, with the potential to enhance patient outcomes globally.
   

From 2024 to 2032, the age-related macular degeneration market in the UK is poised for significant growth.
 

• The National Health Service (NHS) in the UK provides extensive coverage for AMD treatments, encompassing anti-vascular endothelial growth factor (anti-VEGF) injections like Lucentis and Eylea. Thanks to NHS reimbursements, many patients can access these effective therapies with minimal out-of-pocket costs. This broad accessibility is a key driver for the growth of the AMD treatment market in the UK.
   
• The UK has rolled out several screening and public health initiatives aimed at early AMD detection, especially for high-risk groups. Such proactive measures not only facilitate timely interventions but also boost the demand for AMD treatments, as patients are diagnosed at more manageable stages of the condition.
   
• For example, the NHS offers optical vouchers and provides complimentary eye tests every two years for adults aged 60 and above, bolstering early AMD detection. Given these public health initiatives, the demand for AMD treatments is set to persist in the years ahead.
   

Between 2024 and 2032, Japan's age-related macular degeneration market is set for notable growth.
 

• As of 2023, Japan boasts an average life expectancy of 87.14 years for women and 81.09 years for men, placing it among the global leaders, according to the World Health Organization (WHO).
• This remarkable longevity has birthed a swiftly aging populace, with 29.1% of Japanese citizens aged 65 or older in 2023, as highlighted by the BBC. Given that older adults are more susceptible to ophthalmic disorders like AMD, there's a surging demand for treatments to ensure optimal eye care. This demographic trend is poised to fuel the market's growth in Japan.
   
• Moreover, Japan's national healthcare system offers comprehensive coverage for AMD treatments, including anti-VEGF therapies. Such inclusivity in public health insurance not only boosts patient accessibility but also propels market growth.
   

Saudi Arabia's age-related macular degeneration market is set for significant growth from 2024 to 2032.
 

• Chronic conditions like diabetes, hypertension, and obesity are prevalent in Saudi Arabia. The World Health Organization (WHO) reported a diabetes prevalence of 17.7% in Saudi Arabia in 2021. These chronic conditions heighten the risk of age-related macular degeneration (AMD), especially among the elderly.
   
• The International Diabetes Federation highlights that individuals with diabetes face a greater likelihood of developing AMD than those without. Given the rising chronic disease rates, there's an intensified demand for AMD treatment and preventive measures, underscoring the urgent need for comprehensive eye care services in the nation.
   
• Aligned with its Vision 2030 initiative, the Saudi government is channeling significant investments into healthcare infrastructure. This endeavor aims to broaden access to advanced medical care and specialized treatments. With the establishment of new hospitals, clinics, and diagnostic centers, the accessibility of AMD treatments is set to expand for the Saudi populace.